JPRN-jRCT1080225198终止1 期
Phase I Study of Combination Therapy with OBP-301 and Chemoradiotherapy in Patients with Locally Advanced Esophageal Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable(—)
- 性别
- All
入选标准
- •The patient was histologically diagnosed with esophageal cancer (squamous cell carcinoma, adenocarcinoma, etc.) by endoscopic biopsy of the primary esophageal lesion, and had a lesion capable of local injection.
- •- The center of esophageal lesions (primary lesion, intramural metastasis, intraepithelial extension) is located in the thoracic esophagus (8th edition of UICC-TNM). However, if the center of the lesion is more distal than the line 2 cm proximal to the esophagogastric junction (the lower end of the palisade vessels seen endoscopically or the upper edge of the gastric mucosal folds), it is not eligible. Esophageal lesions may be single or multiple.
- •- In the 8th edition of UICC-TNM, cT1N2-3,cT2-3N0-3 of adenocarcinoma and cT1N1-3,cT2-3N0-3 of squamous cell carcinoma without distant metastases on cervical-abdominal CT.
- •- ECOG Performance Status (PS) is 0 to 1.
- •- Radical esophagectomy is not indicated or refused by patient.
- •- Definitive chemoradiation is indicated.
排除标准
- •- Patients with active double cancers that require treatment (synchronous double cancers and metachronous double cancers with a disease-free interval of less than 3 years).
- •However, carcinoma in situ, carcinoma of the pharynx, larynx, carcinoma of the skin, and carcinoma of the prostate that does not require treatment, which are not considered to affect prognosis, are not included in active double cancers. Also, a history of a pathologic stage cancer that has been completely resected with a 3-year relative survival of at least 95% or less is not included in the active double cancer.
- •- The chemotherapy was carried out for esophageal cancer in the past.
- •- If you have previously received radiotherapy for cervical, thoracic and upper abdominal lesions.
研究者
相似试验
已完成
1 期
Phase I Study of Combination Therapy with OBP-301, Atezolizumab and chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck CancerHead and Neck CancerJPRN-jRCT2063200044Fujiwara Toshiyoshi23
已完成
2 期
Phase II Study of Combination Therapy with OBP-301 and Radiotherapy in Patients with Locally Advanced Esophageal Canceresophageal carcinomaJPRN-jRCT1080225033Oncolys BioPharma Inc.37
已完成
1 期
Phase I Study of Combination Therapy with OBP-301, Atezolizumab and Bevacizumab in Patients with Hepatocellular CarcinomaHepatocellular carcinomaJPRN-jRCT2033200223Doi Toshihiko4
Unknown
1 期
A Study of OBP-301 With Radiation Therapy in Patients With Esophageal CancerEsophageal CancerNCT03213054Oncolys BioPharma Inc12
招募中
1 期
Phase I/II trial of combined chemotherapy of Nab-paclitaxel, S-1, and Oxaliplatin for gastric cancer patients with peritoneal metastasis (NSOX study)gastric cancer with peritoneal metastasisJPRN-UMIN000030909Wakayama Medical University, School of Medicine35
